| Recruiting | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated Wit NCT06930625 | Debiopharm International SA | Phase 3 |
| Recruiting | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly NCT07037420 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Effects of Pasireotide Lar Therapy on Bone Metabolism NCT07179926 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Study of MAR002 in Healthy Men NCT07195175 | Marea Therapeutics | Phase 1 |
| Recruiting | Diet in the Management of Acromegaly NCT05401084 | Cedars-Sinai Medical Center | N/A |
| Unknown | Hypoproteic Diet in Acromegaly NCT05298891 | Azienda Ospedaliero Universitaria Maggiore della Carita | N/A |
| Not Yet Recruiting | Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacolo NCT06326853 | IRCCS San Raffaele | — |
| Completed | Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly NCT07100587 | University of Palermo | N/A |
| Completed | A Phase 1 Study of TE-8214 Solution in Healthy Volunteers NCT06372652 | Immunwork, Inc. | Phase 1 |
| Completed | A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) an NCT06253897 | Ipsen | — |
| Recruiting | The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly NCT06597383 | IRCCS San Raffaele | — |
| Completed | Acromegaly: Balance, Falls and Fracture Risk NCT05752825 | Christian Alexander H Rosendal | — |
| Recruiting | Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. NCT06344650 | IRCCS San Raffaele | — |
| Completed | A Single-dose Study of Octreotide Injection in Healthy Adult Subjects NCT05761431 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Withdrawn | Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in Chin NCT05184231 | Ipsen | — |
| Completed | Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands NCT06607666 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Korean Regulatory Post Marketing Surveillance for Somavert NCT05131100 | Pfizer | — |
| Completed | Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China NCT05431803 | Ipsen | — |
| Terminated | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participan NCT05364944 | Debiopharm International SA | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) NCT05192382 | Crinetics Pharmaceuticals Inc. | Phase 3 |
| Unknown | Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery NCT05149495 | University Hospital, Strasbourg, France | — |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly NCT04837040 | Crinetics Pharmaceuticals Inc. | Phase 3 |
| Completed | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acrome NCT04522180 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy NCT04520646 | Huashan Hospital | N/A |
| Unknown | The TMS Treatment for Postoperative Headache in GH Tumor NCT04529356 | Huashan Hospital | N/A |
| Completed | Reproducibility and Utility of OGTT in Acromegaly NCT04066569 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | PegvisOMant and the Immune SystEm (PROMISE) NCT05069324 | University of Roma La Sapienza | — |
| Withdrawn | Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly NCT04003519 | Ipsen | — |
| Active Not Recruiting | A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT NCT04261712 | Crinetics Pharmaceuticals Inc. | Phase 2 |
| Unknown | ACRODAT Prospective Evaluation Study NCT04349839 | University of Aarhus | — |
| Completed | A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly NCT04125836 | Camurus AB | Phase 3 |
| Completed | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly NCT04076462 | Camurus AB | Phase 3 |
| Completed | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting S NCT03967249 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study NCT05964712 | Istituto Auxologico Italiano | — |
| Completed | Vitamin D Metabolism in Patients With Endocrine Disorders NCT04844164 | Endocrinology Research Centre, Moscow | Phase 1 |
| Completed | An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) NCT03789656 | Crinetics Pharmaceuticals Inc. | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) NCT03792555 | Crinetics Pharmaceuticals Inc. | Phase 2 |
| Completed | Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 NCT03849872 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-ac NCT03548415 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients NCT04138537 | Bezmialem Vakif University | N/A |
| Completed | Acromegaly: Patient And Physician Perspectives NCT03613623 | Tulane University | — |
| Terminated | A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers NCT03571594 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Muscle in Acromegaly and Cushing's Syndrome NCT03673761 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Recruiting | The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research NCT03158090 | Ginkgo Leaf Center for Rare Disorders | — |
| Unknown | Acromegaly - Before and After Treatment NCT03431727 | University of Aarhus | — |
| Unknown | Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly NCT03252353 | Chiasma, Inc. | Phase 3 |
| Completed | Strict IGF-1 Control in Acromegaly NCT02952885 | Unity Health Toronto | Phase 3 |
| Terminated | Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly NCT03045302 | Ipsen | Phase 2 |
| Unknown | Buccodental Manifestations in Patients With Acromegaly NCT03401008 | University Hospital, Clermont-Ferrand | — |
| Completed | Treatment Patterns and Treatment Outcomes for Acromegaly NCT03043586 | Columbia University | — |
| Completed | Dynamic Hormone Diagnostics in Endocrine Disease NCT02934399 | Haukeland University Hospital | — |
| Completed | Bone MicroArchitecture in Acromegaly NCT03225040 | Columbia University | — |
| Completed | Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects NCT02807233 | Ipsen | — |
| Completed | Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly NCT02685709 | Chiasma, Inc. | Phase 3 |
| Unknown | Rehabilitation Program in Patients With Acromegaly NCT03710499 | Centro Universitário Augusto Motta | N/A |
| Terminated | Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg NCT02698384 | Ipsen | — |
| Unknown | Pasireotide LAR and Pegvisomant Study in Acromegaly NCT02668172 | Erasmus Medical Center | Phase 4 |
| Completed | Validation Study of the SAGIT® Instrument in Acromegaly NCT02539927 | Ipsen | — |
| Completed | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues NCT02354508 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Seoul National University Pituitary Disease Cohort Study NCT03474601 | Seoul National University Hospital | — |
| Unknown | Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation NCT02403414 | All India Institute of Medical Sciences | — |
| Completed | Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonge NCT02396953 | Ipsen | Phase 1 / Phase 2 |
| Completed | Late Effects of Radiosurgery on Acromegaly Study NCT02296216 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours NCT02299089 | Camurus AB | Phase 2 |
| Completed | Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment. NCT02396966 | Ipsen | — |
| Completed | Cardiac (CMRI) Assessment of Acromegaly NCT02948322 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Acromegaly & Sleep Apnoea NCT02371057 | The Leeds Teaching Hospitals NHS Trust | — |
| Completed | Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Ac NCT02493517 | Ipsen | Phase 3 |
| Unknown | Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly NCT02115906 | Medical University of Vienna | — |
| Terminated | Predictive Factors Study NCT02020499 | Ipsen | — |
| Completed | Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Pos NCT02152124 | University Hospital, Ghent | — |
| Completed | Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegal NCT02060383 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Phase II Study With ITF2984 in Acromegalic Patients NCT02111044 | Italfarmaco | Phase 2 |
| Completed | IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly NCT02084095 | Carol Davila University of Medicine and Pharmacy | — |
| Unknown | Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analog NCT02427295 | Asan Medical Center | Phase 4 |
| Completed | Programme of Acromegaly Screening in Patients With Associated Somatic Disorders NCT02020967 | Ipsen | — |
| Completed | The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics NCT02217800 | Aspireo Pharmaceuticals Limited | Phase 2 |
| Completed | Description of Sign-and-symptom Associations at Acromegaly Diagnosis. NCT02012127 | Ipsen | — |
| Unknown | Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. NCT02092129 | Rigshospitalet, Denmark | — |
| Completed | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored NCT01794793 | RECORDATI GROUP | Phase 4 |
| Terminated | A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. NCT01861717 | Saint John's Cancer Institute | Phase 4 |
| Completed | Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly NCT01819883 | Massachusetts General Hospital | — |
| Unknown | Brain-gut Interaction in Irradiated Patients With Acromegaly NCT02005978 | Rigshospitalet, Denmark | — |
| Unknown | Epidemiology of Acromegaly in Denmark 1991-2010 NCT01752621 | University of Aarhus | — |
| Completed | SAGIT for Classification of Patients With Acromegaly in Clinical Practice NCT02231593 | Ipsen | — |
| Completed | Acromegaly Treatment Quality of Life Study NCT01732406 | Massachusetts General Hospital | — |
| Completed | Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects NCT01723748 | University of Aarhus | N/A |
| Unknown | Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly NCT01902420 | TC Erciyes University | — |
| Completed | Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary NCT01673646 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. NCT02235987 | Aspireo Pharmaceuticals Limited | Phase 2 |
| Completed | Somatuline Predictive Factors in Acromegaly and NET NCT01840449 | Ipsen | — |
| Recruiting | Developing a Simple Recognition System of Acromegaly NCT03042026 | National Taiwan University Hospital | — |
| Completed | Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target NCT01618513 | University of Aarhus | Phase 4 |
| Unknown | Prospective Study on Changes in Acromegaly NCT01612624 | Radboud University Medical Center | — |
| Terminated | Acromegaly Combination Treatment Study NCT01538966 | Cedars-Sinai Medical Center | N/A |
| Completed | Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly NCT01412424 | Chiasma, Inc. | Phase 3 |
| Completed | One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma NCT01471405 | Ipsen | — |
| Completed | Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pit NCT01568359 | Emory University | — |
| Completed | Rhinological Outcomes in Endonasal Pituitary Surgery NCT01504399 | St. Joseph's Hospital and Medical Center, Phoenix | — |
| Withdrawn | Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs NCT01371045 | Cedars-Sinai Medical Center | — |
| Unknown | The Observational Study of Growth Hormone-secreting Pituitary Tumors NCT01368133 | Huashan Hospital | — |
| Completed | Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment NCT01302652 | Massachusetts General Hospital | — |
| Terminated | Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly NCT01295060 | Endo Pharmaceuticals | Phase 3 |
| Completed | Clomiphene Citrate for Treatment of Acromegaly NCT02274311 | Felipe Henning Gaia Duarte | Phase 2 |
| Completed | Tissue Biomarker for Pegvisomant Action NCT01261000 | Cedars-Sinai Medical Center | N/A |
| Completed | Study in Polish Acromegalic Patients Treated With Somatuline Autogel NCT01333384 | Ipsen | — |
| Completed | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) NCT01137682 | Novartis Pharmaceuticals | Phase 3 |
| Suspended | Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ® NCT01086982 | Azidus Brasil | Phase 1 |
| Unknown | Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Pati NCT04860037 | University Hospital, Montpellier | — |
| Terminated | Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly NCT00994214 | Ipsen | Phase 2 |
| Completed | Peripheral Metabolic Effects of Somatostatin NCT01062529 | University of Aarhus | N/A |
| Completed | Surgical Versus Medical Treatment of Acromegaly NCT01000090 | University of Aarhus | — |
| Unknown | Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. NCT01265121 | University of Sao Paulo General Hospital | N/A |
| Completed | Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) NCT00915954 | Cedars-Sinai Medical Center | N/A |
| Completed | Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic S NCT00701363 | Ipsen | Phase 4 |
| Terminated | Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly NCT00765323 | Endo Pharmaceuticals | Phase 3 |
| Completed | Non Interventional Post Marketing Programme in Acromegaly NCT00747500 | Ipsen | — |
| Completed | Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients NCT00652379 | University of Aarhus | N/A |
| Withdrawn | Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) NCT00517491 | Ipsen | Phase 2 |
| Completed | Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma NCT00690898 | Ipsen | Phase 3 |
| Completed | Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study NCT00686348 | Ipsen | — |
| Completed | Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance NCT00663000 | University Hospital Tuebingen | — |
| Completed | Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acrome NCT00600886 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients NCT00642421 | Ambrilia Biopharma, Inc. | Phase 3 |
| Completed | Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment NCT00647179 | University of Aarhus | — |
| Completed | Acute Application of Pegvisomant and Octreotide in Acromegaly NCT00595140 | Ludwig-Maximilians - University of Munich | Phase 4 |
| Withdrawn | Inter-Assay Growth Hormone and IGF-I Variability NCT00638287 | Cedars-Sinai Medical Center | — |
| Completed | Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients NCT00635765 | Ambrilia Biopharma, Inc. | Phase 3 |
| Completed | Physiopathology of Sodium Retention in Acromegaly NCT00531908 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Follo NCT00500227 | Ipsen | — |
| Completed | Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan NCT00658879 | Pfizer | — |
| Completed | Ultrasound Guided Octreotide LAR Injection in Acromegaly NCT00552071 | Cedars-Sinai Medical Center | Phase 4 |
| Completed | Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States NCT00461240 | Barts & The London NHS Trust | — |
| Completed | Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel NCT00447499 | Ipsen | Phase 3 |
| Completed | Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients NCT00616551 | Ambrilia Biopharma, Inc. | Phase 3 |
| Recruiting | Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA NCT00461188 | Barts & The London NHS Trust | — |
| Completed | Open Label Study of Octreotide Implant in Patients With Acromegaly NCT00913055 | Endo Pharmaceuticals | Phase 2 |
| Completed | Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patient NCT00642720 | Erasmus Medical Center | Phase 4 |
| Completed | Effects of Sandostatin LAR® in Acromegaly NCT01424241 | Columbia University | Phase 4 |
| Completed | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients NCT00383708 | Ipsen | Phase 3 |
| Completed | Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-rec NCT01278342 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With NCT00552851 | University of Wuerzburg | Phase 4 |
| Completed | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcino NCT00446082 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly NCT00921609 | Cedars-Sinai Medical Center | — |
| Unknown | Estrogen Treatment in Acromegalic Women NCT00315107 | Université de Montréal | Phase 2 |
| Completed | Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly NCT00376064 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly NCT00372697 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients NCT01014793 | Federal University of São Paulo | — |
| Completed | Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly NCT00444873 | Ipsen | Phase 3 |
| Completed | Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone NCT01029275 | University Hospital, Rouen | N/A |
| Completed | Canadian Pegvisomant Compassionate Study In Acromegalic Patients NCT00151437 | Pfizer | Phase 4 |
| Completed | An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly NCT00171730 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Defi NCT00182091 | Massachusetts General Hospital | N/A |
| Completed | Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR NCT00216398 | Ipsen | Phase 4 |
| Completed | Long Term Study With B2036-PEG NCT00143416 | Pfizer | Phase 3 |
| Completed | Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients NCT00088582 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Somatuline Autogel: Acromegaly Self/Partner Injection Study NCT00149188 | Ipsen | Phase 4 |
| Completed | Non Interventional Study For Patients Treated With Somavert® NCT00858143 | Pfizer | — |
| Unknown | Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas NCT00993356 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Completed | Pegvisomant And Sandostatin LAR Combination Study NCT00068029 | Pfizer | Phase 4 |
| Completed | A Prospective Study of Outcome After Therapy for Acromegaly NCT01809808 | Columbia University | — |
| Completed | A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Ac NCT00234520 | Ipsen | — |
| Completed | A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Ac NCT00068042 | Pfizer | Phase 4 |
| Terminated | Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macro NCT00242541 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly NCT00627796 | Federico II University | Phase 4 |
| Completed | Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients NCT00128232 | Novartis | Phase 3 |
| Completed | Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Trea NCT00225979 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction NCT00145405 | Odense University Hospital | Phase 4 |
| Completed | Octreotide Efficacy and Safety in First-line Acromegalic Patients NCT00171886 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Fractionated Stereotactic Radiotherapy in Patients With Acromegaly NCT00934271 | Rigshospitalet, Denmark | — |
| Completed | Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly NCT00499993 | Ipsen | Phase 3 |
| Completed | Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients NCT00210457 | Ipsen | Phase 3 |
| Completed | Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly NCT00234572 | Ipsen | Phase 2 / Phase 3 |
| Completed | Preoperative Octreotide Treatment of Acromegaly NCT00521300 | St. Olavs Hospital | Phase 4 |
| Unknown | Measurement of Outcome of Surgical Treatment in Patients With Acromegaly NCT00005100 | National Center for Research Resources (NCRR) | — |
| Completed | Sandostatin LAR Depot vs. Surgery for Treating Acromegaly NCT00001860 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Cardiovascular Outcome After Surgery or Somatostatin Analogues NCT00615004 | Federico II University | — |
| Completed | Prediction of Tumor Shrinkage in Acromegaly NCT00616408 | Federico II University | — |
| Completed | Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly NCT00703079 | Federico II University | — |
| Completed | Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly NCT00461149 | Federico II University | Phase 4 |
| Completed | Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly NCT00004332 | National Center for Research Resources (NCRR) | — |
| Completed | The Treatment and Natural History of Acromegaly NCT00001981 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Approved For Marketing | An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly NCT01995734 | Novartis Pharmaceuticals | — |
| Unknown | Lanreotide Levels in Acromegaly NCT00916916 | Cedars-Sinai Medical Center | — |